C
Carmelo A. Milano
Researcher at Duke University
Publications - 418
Citations - 26139
Carmelo A. Milano is an academic researcher from Duke University. The author has contributed to research in topics: Ventricular assist device & Transplantation. The author has an hindex of 67, co-authored 377 publications receiving 21286 citations. Previous affiliations of Carmelo A. Milano include Papworth Hospital & Durham University.
Papers
More filters
Journal ArticleDOI
Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist Device
Mark S. Slaughter,Joseph G. Rogers,Carmelo A. Milano,Stuart D. Russell,John V. Conte,David S. Feldman,Benjamin Sun,Antone Tatooles,Reynolds M. Delgado,James W. Long,Thomas C. Wozniak,Waqas Ghumman,David J. Farrar,O. Howard Frazier +13 more
TL;DR: Treatment with a continuous-flow left ventricular assist device in patients with advanced heart failure significantly improved the probability of survival free from stroke and device failure at 2 years as compared with a pulsatile device.
Journal ArticleDOI
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Paul A. Heidenreich,Biykem Bozkurt,David Aguilar,Larry A. Allen,Joni J. Byun,Monica Colvin,Anita Deswal,Mark H. Drazner,Shannon M. Dunlay,Linda R. Evers,James C. Fang,Savitri Fedson,Gregg C. Fonarow,Salim S. Hayek,Adrian F. Hernandez,Prateeti Khazanie,Michelle M. Kittleson,Christopher S. Lee,Mark S. Link,Carmelo A. Milano,Lorraine C. Nnacheta,Alexander T. Sandhu,Lynne W. Stevenson,Orly Vardeny,Amanda R. Vest,Clyde W. Yancy +25 more
TL;DR: The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" as discussed by the authors provides patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure.
Journal ArticleDOI
Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: Incidence, risk factors, and effect on outcomes
Robert L. Kormos,Jeffrey J. Teuteberg,Francis D. Pagani,Stuart D. Russell,Ranjit John,Leslie W. Miller,Todd Massey,Carmelo A. Milano,Nader Moazami,Kartik S. Sundareswaran,David J. Farrar +10 more
TL;DR: The incidence of right ventricular failure in patients with a HeartMate II ventricular assist device is comparable or less than that of patients with pulsatile-flow devices and might benefit from preoperative optimization of right heart function or planned biventricular support.
Journal ArticleDOI
Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation
Robert E. Michler,Peter K. Smith,Michael K. Parides,Gorav Ailawadi,Vinod H. Thourani,Alan J. Moskowitz,Michael A. Acker,Judy Hung,Helena L. Chang,Louis P. Perrault,A. Marc Gillinov,Michael Argenziano,Emilia Bagiella,Jessica Overbey,Ellen Moquete,Lopa N. Gupta,Marissa A. Miller,Wendy C. Taddei-Peters,Neal Jeffries,Richard D. Weisel,Eric A. Rose,James S. Gammie,James S. Gammie,Joseph J. DeRose,John D. Puskas,François Dagenais,Sandra G. Burks,Ismail El-Hamamsy,Carmelo A. Milano,Pavan Atluri,Pierre Voisine,Patrick T. O'Gara,Annetine C. Gelijns +32 more
TL;DR: Mitral-valve repair provided a more durable correction of mitral regurgitation but did not significantly improve survival or reduce overall adverse events or readmissions and was associated with an early hazard of increased neurologic events and supraventricular arrhythmias.
Journal ArticleDOI
Outcomes of Left Ventricular Assist Device Implantation as Destination Therapy in the Post-REMATCH Era: Implications for Patient Selection
Katherine Lietz,Katherine Lietz,Katherine Lietz,James W. Long,Abdallah G. Kfoury,Mark S. Slaughter,Marc A. Silver,Carmelo A. Milano,Joseph G. Rogers,Yoshifumi Naka,Donna Mancini,Leslie W. Miller,Leslie W. Miller +12 more
TL;DR: Outcomes of DT in the post-REMATCH era in the United States are described, finding that patients with advanced heart failure who are referred for DT before major complications of heart failure develop have the best chance of achieving an excellent 1-year survival with LVAD therapy.